Pentixapharm Holding AG engages in the development of radiopharmaceutical approaches for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases. The company was founded in 2024 and is headquartered in Wuerzburg, Germany.